Costanza Rovida
CAAT Europe, University of Konstanz, Germany
Nathalie Alépée
L’Oréal R&I, Aulnay, France
Anne M. Api
Research Institute for Fragrance Materials, Inc., Woodcliff Lake, USA
David A. Basketter
DABMEB Consultancy Ltd, Sharnbrook, UK
Frédéric Y. Bois
INERIS, DRC/VIVA/METO, Verneuil en Halatte, France
Francesca Caloni
Università degli Studi di Milano, Department of Health, Animal Science and Food Safety (VESPA), Milan, Italy
Emanuela Corsini
Università degli Studi di Milano, Department of Pharmacological and Biomolecular Sciences (DISFEB), Milan, Italy
Mardas Daneshian
CAAT Europe, University of Konstanz, Germany
Chantra Eskes
European Society of Toxicology In Vitro, La croix Saint Ouen, France
Janine Ezendam
National Institute for Public Health and the Environment (RIVM), Centre for Health Protection, Bilthoven, The Netherlands
Horst Fuchs
CellSystems GmbH, Troisdorf, Germany
Patrick Hayden
MatTek Corp., Ashland, MA, USA
Christa Hegele-Hartung
Bayer AG, West Haven, USA
Sebastian Hoffmann
seh consulting + services, Paderborn, Germany
Bruno Hubesch
Cefic LRI and EPAA, Brussels, Belgium; Hubesch Consult BVBA, Sint-Pieters-Leeuw, Belgium
Miriam N. Jacobs
Scientific Committee and Emerging Risks Unit, European Food Safety Authority, Parma, Italy; current address Centre for Radiation, Chemical and Environmental Hazards, Public Health England, UK
Joanna Jaworska
Procter & Gamble, Modelling & Simulation Biological Systems, Brussels Innovation Center, Strombeek-Bever, Belgium
André Kleensang
Center for Alternatives to Animal Testing (CAAT), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Nicole Kleinstreuer
ILS/NICEATM, Research Triangle Park, NC, USA
Jon Lalko
Research Institute for Fragrance Materials, Inc., Woodcliff Lake, USA
Robert Landsiedel
BASF SE, Ludwigshafen, Germany
Frédéric Lebreux
Laboratoire de Synthèse Organique, CNRS UMR 7652, Ecole Polytechnique, Palaiseau, France
Thomas Luechtefeld
Center for Alternatives to Animal Testing (CAAT), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Monica Locatelli
REACH Mastery, Como, Italy
Annette Mehling
BASF SE, Ludwigshafen, Germany
Andreas Natsch
Givaudan Schweiz AG, Dübendorf, Switzerland
Jonathan W. Pitchford
Departments of Biology and Mathematics, University of York, UK
Donald Prater
Food and Drug Administration, European Bureau, Brussels, Belgium
Pilar Prieto
EURL ECVAM, Systems Toxicology Unit, Institute for Health and Consumer Protection, European Commission, Joint Research Centre, Ispra, Italy
Andreas Schepky
Beiersdorf AG, Hamburg, Germany
Gerrit Schüürmann
UFZ Department of Ecological Chemistry, Helmholtz Centre for Environmental Research, Leipzig, Germany; Institute for Organic Chemistry, Technical University Bergakademie Freiberg, Germany
Lena Smirnova
Center for Alternatives to Animal Testing (CAAT), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Colleen Toole
CeeTox Inc., Kalamazoo, MI, USA
Erwin van Vliet
SeCAM Services & Consultation on Alternative Methods, Agno, Switzerland
Dirk Weisensee
CellSystems GmbH, Troisdorf, Germany
Thomas Hartung
CAAT Europe, University of Konstanz, Germany; Center for Alternatives to Animal Testing (CAAT), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Abstract
Integrated testing strategies (ITS), as opposed to a single definitive test or fixed batteries of tests, are expected to efficiently combine different information sources in a quantifiable fashion to satisfy an information need, in this case for regulatory safety assessments. With increasing awareness of the limitations of each individual tool and the development of highly targeted tests and predictions, the need for combining pieces of evidence increases. The discussions that took place during this workshop, which brought together a group of experts coming from different related areas, illustrate the current state of the art of ITS, as well as promising developments and identifiable challenges. The case of skin sensitization was taken as an example to understand how possible ITS can be constructed, optimized and validated. This will require embracing and developing new concepts such as adverse outcome pathways (AOP), advanced statistical learning algorithms and machine learning, mechanistic validation and “Good ITS Practices”.
